LEN vs PEN · rev $34.19B vs P/E 237, rev $1.19B
LEN (LEN) versus Penumbra Inc (PEN) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Penumbra Inc (PEN) is a medical devices company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported PEN revenue for 2024-12-31 was $1.19B. Net income was $14.0M. Revenue was up 319.6% from 2023-12-31 to 2024-12-31. PEN currently screens at market cap $9.93B and trailing P/E 237.4.
LEN currently screens at market cap $0. PEN currently screens at market cap $9.93B and trailing P/E 237.4.
Not investment advice. Open the LEN and PEN stock pages for the full models.
Not investment advice.